FDA Posts Public Meeting Documents

FDA has posted the slides and transcript of the FDA Public Meeting on the Final Assessment of the Program for Enhanced Review Transparency and Communication in PDUFA V, held March 27, 2017, in Silver Spring, Md., as well as other documents related to evaluation of the PDUFA V Program.

Meetings and Events Bulletin Board

Highlights from the 2018 IPPC +

Mr. Jan M. Bult, President & CEO, PPTA, opened the well-attended IPPC 2018 by welcoming the more than 300 attendees to Budapest. PPTA thanks its sponsors who help make the IPPC possible every year.
Read More
2018 Plasma Protein Forum Highlights +

Opening Session: Jan M. Bult, President and CEO of PPTA, opened the 2018 Plasma Protein Forum by welcoming attendees to Washington, DC. He then introduced the “How Is Your Day?” campaign to PPTA’s North America audience, highlighting the campaign’s goals and purpose. Mr. Bult acknowledged attendees living with rare diseases who have offered testimonials in support of the campaign – Tim Frost, Ed Burke, Chris Templin, and Terry Halper.
Read More

Regulatory Policy Bulletin Board

Public Workshop Focuses on Immune Globulin Products +

On Nov. 8-9, the U.S. Food and Drug Administration (FDA) is conducting a public workshop entitled "Immune Globulin Potency in the 21st Century." The purpose of the public workshop is to discuss new challenges to meet U.S. potency requirements for Immune Globulin (IG) products and to identify measures to address these challenges.
Read More
FDA Posts Public Meeting Documents +

FDA has posted the slides and transcript of the FDA Public Meeting on the Final Assessment of the Program for Enhanced Review Transparency and Communication in PDUFA V, held March 27, 2017, in Silver Spring, Md., as well as other documents related to evaluation of the PDUFA V Program.
Read More
115th meeting of the FDA Blood Products Advisory Committee +

On April 4, PPTA staff attended the 115th meeting of the FDA Blood Products Advisory Committee in Silver Spring, Md. In the morning, the Biologics License Application of Novo Nordisk's Recombinant Human Coagulation Factor IX, GlycoPEGylated, was discussed. Committee comments focused on the safety of the product, including risks in the intended population, particularly in the pediatric and elderly populations, and in the setting of life-time administration, and whether monitoring—particularly of neurologic function—should be provided for the safety of patients or study subjects.
Read More